- Home
- RGS vs ANL Comparison
RGS vs ANL Comparison
Compare RGS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGS
- ANL
- Stock Information
- Founded
- RGS 1922
- ANL 2004
- Country
- RGS United States
- ANL Cayman Islands
- Employees
- RGS N/A
- ANL N/A
- Industry
- RGS Other Consumer Services
- ANL
- Sector
- RGS Consumer Discretionary
- ANL
- Exchange
- RGS Nasdaq
- ANL Nasdaq
- Market Cap
- RGS 70.8M
- ANL 61.8M
- IPO Year
- RGS 1991
- ANL 2023
- Fundamental
- Price
- RGS $29.50
- ANL $1.66
- Analyst Decision
- RGS
- ANL Hold
- Analyst Count
- RGS 0
- ANL 1
- Target Price
- RGS N/A
- ANL N/A
- AVG Volume (30 Days)
- RGS 11.9K
- ANL 7.5K
- Earning Date
- RGS 11-12-2025
- ANL 11-04-2025
- Dividend Yield
- RGS N/A
- ANL N/A
- EPS Growth
- RGS 20.23
- ANL N/A
- EPS
- RGS 46.10
- ANL N/A
- Revenue
- RGS $210,134,000.00
- ANL N/A
- Revenue This Year
- RGS N/A
- ANL N/A
- Revenue Next Year
- RGS N/A
- ANL N/A
- P/E Ratio
- RGS $0.70
- ANL N/A
- Revenue Growth
- RGS 3.52
- ANL N/A
- 52 Week Low
- RGS $15.00
- ANL $1.10
- 52 Week High
- RGS $31.50
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- RGS 55.18
- ANL 46.31
- Support Level
- RGS $29.33
- ANL $1.60
- Resistance Level
- RGS $30.50
- ANL $1.73
- Average True Range (ATR)
- RGS 0.93
- ANL 0.07
- MACD
- RGS -0.24
- ANL -0.01
- Stochastic Oscillator
- RGS 35.21
- ANL 42.40
About RGS Regis Corporation
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.